More Business Wire
View Older Stories View Newer Stories-
Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track
-
International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone
-
Hoffmann Green Reports Robust Half-Year Revenue Growth and Continues Executing Its Strategic Roadmap
-
Juniper Research: Quantum Computing - Commercial Revenue to Near $10bn Globally by 2030
-
The ICAPE Group Announces a Major Acquisition to Become One of the Leading Players in PCB Distribution in Japan
-
The Eurofins Network Expands Its BioPharma Product Testing Offering in the United States With the Acquisition of Infinity Laboratories, Inc.
-
e.l.f. SKIN Is Salvation to Skincare Shame in Satirical “Divine Skintervention” Campaign
-
Circle and Sony Block Solutions Labs to Enable USDC on Soneium to Empower a Creator Economy
-
Alvarez & Marsal Tax Expands Across Asia Pacific Hiring James Badenach as Managing Director to Lead New Regional Offering
-
Masimo Shares Final Thoughts Ahead of September 19 Annual Meeting Where Everything is at Stake
-
Pilbara Aboriginal artists share cultural stories for the 19th Colours of our Country exhibition
-
Stonepeak-backed MIDC Completes Combination with PhilTower
-
Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk
-
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phas
-
Alcoa Announces Agreement to Sell its 25.1% Stake in Ma’aden Joint Venture to Ma’aden
-
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
-
Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid
-
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
-
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Pro
-
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
-
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
-
Platform Science to Acquire Trimble’s Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology
-
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
-
Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers
-
Cierto Tequila Wins Tequila of the Year at the 2024 Melbourne International Spirits Competition
-
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
-
Cierto Tequila Named Tequila of the Year at the 2024 Asia International Spirits Competition
-
Dongfeng Embarks on a New Journey in Europe, Various New Products Debuted Offer Diversified Mobility Options
-
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unre
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
-
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
-
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
-
University of Phoenix Continues to Empower Young Learners at Hackathon Jr. Event
-
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
-
SVTA Announces New Board Officers
-
Irdeto Partners with Bitmovin to Deliver Industry-Leading Secure Low-Latency Streaming with Unmatched User Experience
-
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positi
-
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug
-
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
-
Masimo Partners with Google to Develop a Reference Platform That Helps Device Manufacturers Bring High-performing Wear OS Smartwatches to Market
-
SCF Acquires Newpark Fluids Systems
-
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Masimo Issues Statement Following Court’s Order Holding Politan and Quentin Koffey in Contempt and Finding Politan Made False Statements to Stockholders
-
Houston Rapper Files Federal Lawsuit Against City of Houston and Police Officers for Wrongful Arrest and Imprisonment
-
Tom’s Truck Center Becomes First U.S. Commercial Truck Dealer with Onsite Hydrogen Refueling Station
-
Owlet Announces Closing of Public Offering and Comprehensive Debt Refinancing for Total Gross Proceeds of up to $46.6 Million
-
Best’s Commentary: Growing Gulf Coast-Focused Insurers Face Key Test in Hurricane Francine
-
Jack Nathan Health Signs Letter of Intent
